[Rho-kinase inhibitors]

Nihon Yakurigaku Zasshi. 2011 Sep;138(3):112-6. doi: 10.1254/fpj.138.112.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / therapeutic use
  • Amides / pharmacology
  • Amides / therapeutic use*
  • Animals
  • Clinical Trials as Topic
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / etiology
  • Drug Design*
  • Glaucoma / drug therapy
  • Glaucoma / etiology
  • Humans
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / etiology
  • Mice
  • Molecular Targeted Therapy*
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Rats
  • Vasospasm, Intracranial / drug therapy
  • Vasospasm, Intracranial / etiology
  • rho-Associated Kinases / antagonists & inhibitors*
  • rho-Associated Kinases / physiology*

Substances

  • Amides
  • Pyridines
  • Y 27632
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • ROCK1 protein, human
  • ROCK2 protein, human
  • rho-Associated Kinases
  • fasudil